<span>OECD 443 Regulatory Recommendations</span>
January 10, 2022

OECD 443 Regulatory Recommendations

The Extended One Generation Reproductive Toxicity Study (EOGRTS, EU B.56, OECD TG 443) has been the information requirement for reproductive toxicity under the Registration, Evaluation, Authorization, and Restriction of Chemicals (REACH, Annexes IX and X, Section 8.7.3.) since March 2015.
<span>Intensive BMO Preparation is Key</span>
January 12, 2022

Intensive BMO Preparation is Key

A medical device manufacturer conducted a successful randomized IDE clinical trial, but at the time of study closure they decided not to file the Premarket Approval (PMA) application for business reasons. However, five years later, the business climate had improved and the company proceeded with its PMA application.
<span>Safety First: Your Guide to the Toxic Substances Control ACT (TSCA)</span>
January 31, 2022

Safety First: Your Guide to the Toxic Substances Control ACT (TSCA)

All governments are keen to ensure that the chemicals produced, manufactured and used within their countries are safe for consumers and used appropriately. The 2007 European Union Registration, Evaluation, Authorization and Restriction of Chemicals (REACH) regulation has become a model globally and is hazard based. In contrast, the U.S.
<span>Accelerating Biomarker-Driven Oncology Drug Development</span>
February 1, 2022

Accelerating Biomarker-Driven Oncology Drug Development

Your mission is to transform oncology patient care. Our mission is to help you do it better, faster and more efficiently. Learn more about how Labcorp Oncology can help in your development from initial discovery to post-marketing and commercialization.